HomeREGULATORY
REGULATORY

MHLW to Issue Optimal Use Guidelines for Bavencio
(Nov.16.2017)

The Ministry of Health, Labor and Welfare (MHLW) will issue “optimal use promotion guidelines” for Merck Serono’s Bavencio (avelumab), Japan’s first PD-L1 inhibitor approved on November 15 for its listing later this month ...
(LOG IN FOR FULL STORY)